RetinalGenix Technologies (RTGN) Liabilities and Shareholders Equity (2020 - 2026)

RetinalGenix Technologies has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $5805.0 for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $5805.0, down 51.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $42235.0 (down 79.17% YoY), and the FY2025 annual result was $21041.0, up 40.78% from the prior year.
• Liabilities and Shareholders Equity came in at $5805.0 for Q1 2026 at RetinalGenix Technologies, down from $21041.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $88854.0 in Q3 2024 to a low of $27.0 in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $7001.0 (2025), against an average of $18381.9.
• Across the five-year window, Liabilities and Shareholders Equity plunged 94.25% in 2023 and surged 39390.67% in 2024, its largest moves.
• RetinalGenix Technologies' Liabilities and Shareholders Equity stood at $294.0 in 2022, then sank by 46.94% to $156.0 in 2023, then jumped by 9480.77% to $14946.0 in 2024, then surged by 40.78% to $21041.0 in 2025, then slumped by 72.41% to $5805.0 in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $5805.0 (Q1 2026), $21041.0 (Q4 2025), and $7001.0 (Q3 2025), per Business Quant data.